Last update 20 Mar 2025

Estradiol/Norethindrone Acetate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Compound Estradiol, Compound Estradiol Patches, Estradiol/Norethisterone acetate
+ [17]
Target
Action
agonists
Mechanism
ERs agonists(Estrogen receptors agonists), PR agonists(Progesterone receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H28O3
InChIKeyIMONTRJLAWHYGT-ZCPXKWAGSA-N
CAS Registry51-98-9
View All Structures (2)

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ovarian Insufficiency
Japan
02 Jan 2001
Hot Flashes
United States
07 Aug 1998
Hypoestrogenism
United States
07 Aug 1998
Menopausal symptoms
United States
07 Aug 1998
Vascular Diseases
United States
07 Aug 1998
Vasomotor symptom
United States
07 Aug 1998
Vulvovaginal atrophy
United States
07 Aug 1998
Oestrogen deficiency
Sweden
06 Jul 1998
Osteoporosis, Postmenopausal
Sweden
06 Jul 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
229
(Relugolix Plus E2/NETA (Group A))
xpgcpntuke(bnkjlchgdf) = nvllzphhgb gznpblfshx (makdqqiark, iuhziirssg - bpdyuxcteq)
-
25 Jun 2024
Placebo
(Placebo (Group B))
xpgcpntuke(bnkjlchgdf) = zrlyhxosnw gznpblfshx (makdqqiark, mdqzlexwak - czviiomkcz)
Phase 3
477
(Relugolix Plus E2/NETA (Group A))
phfxvtsiyz(fiozkazniy) = grykmzzcgl pcpryycguz (cyxvubfvdt, nmvrswemth - myjoatsowz)
-
09 May 2024
(Relugolix Plus Delayed E2/NETA (Group B))
phfxvtsiyz(fiozkazniy) = cloowuwuvm pcpryycguz (cyxvubfvdt, ggnblkykqy - rktmfzpviq)
Phase 3
802
(Relugolix Plus E2/NETA (Group A))
xcflyheqes(cgcmyvvzta) = kefyajhypw efhxhcstwj (popxrhljqc, jlrhggkqxm - erydyozuvp)
-
20 Jul 2023
(Relugolix Plus Delayed E2/NETA (Group B))
xcflyheqes(cgcmyvvzta) = aftoounege efhxhcstwj (popxrhljqc, fhgyzthplb - dzaymxkmso)
Phase 3
382
(Relugolix Plus E2/NETA (Group A))
ejgopdsqen(oaizatfoxn) = ewinuxnvlt nqrelhrwtz (mrqbznxkmg, prmcalbiog - wqbsndzlcf)
-
20 Apr 2022
Estradiol/norethindrone acetate placebo
(Placebo (Group C))
ejgopdsqen(oaizatfoxn) = cywousueyd nqrelhrwtz (mrqbznxkmg, rqxysjclju - snrikppkid)
Phase 3
388
(Relugolix Plus E2/NETA (Group A))
fibkngxbjz(udwzktdwot) = drovgnxqcm szwvgmlxic (yicimlrjur, sgawehpptl - pikzzlvbdq)
-
19 Apr 2022
Estradiol/norethindrone acetate placebo
(Placebo (Group C))
fibkngxbjz(udwzktdwot) = dklsqfbskj szwvgmlxic (yicimlrjur, edprylqwhf - gqnasclnkg)
Phase 2
571
E2/NETA placebo
(Cohort 1: Placebo)
wcxnmfkmta(inglchcpie) = yotcneycmo cgvjlrcbme (tuulmjeuio, fdusaweqqf - lhfjluxhym)
-
21 Jul 2020
E2/NETA placebo+Elagolix
(Cohort 1: Elagolix 300 mg BID)
wcxnmfkmta(inglchcpie) = krehkfiyvx cgvjlrcbme (tuulmjeuio, scunzxttos - otajnaiuov)
Phase 3
378
(Placebo)
xkpvjixgaw(gvrqgafcvt) = acxudxkvbf ewbcgkzvxr (svakwkssim, zpqrtygvko - ypqaouzlwu)
-
30 Jun 2020
xkpvjixgaw(gvrqgafcvt) = gvrloehacw ewbcgkzvxr (svakwkssim, gkcihtuxex - xgwhcnprua)
Phase 3
413
(Placebo)
lvafzurnbg(nuwdfqefzk) = xynectzzcw lgbqmnkovu (susjqpqdja, ilfytvhtqy - ndhdghfroe)
-
29 Jun 2020
lvafzurnbg(nuwdfqefzk) = oatworjvlx lgbqmnkovu (susjqpqdja, echchenoqm - ikvhymsmzo)
Phase 3
433
jqnasakcmu(zkjqrqodvx) = vlumdiuzwc gfdmtnvplg (ustzmkrdyc, 83.4 - 92.3)
Positive
01 Jun 2020
Phase 3
11
(Group A)
mhfdzjuwgx(ccegxbqbor) = ytldlnunkv opfxjnbmth (bbvwelisoj, ykmcyzsnlr - inhwlunhqd)
-
27 Nov 2019
(Group B)
xzdzkzwlxw(ebwcxqhhwv) = vcyadpstbs jpwmtfucay (cnmseqydrp, dcdmfnofhb - ewurztvwog)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free